| Name | Title | Contact Details |
|---|
Delinia has assembled a leadership team, Board of Directors and Scientific Advisory Board comprised of experienced investors, world-class academicians and industry veterans with proven track records for building exceptional life sciences companies.
Q32 Bio is a biotechnology company developing therapeutics targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Priovant Therapeutics is a clinical stage biotechnology company developing targeted therapies for patients with severe autoimmune disease.
Colorado BioScience Association is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuron23™ Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases.